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In vitro stimulation of EMT
Heterozygote germline mutations in the aryl-hydrocarbon receptor interacting protein (AIP) gene play a role in the pathogenesis of pituitary adenoma development in familial isolated pituitary adenoma (FIPA) as well as simplex pituitary adenoma cases. AIP mutation positive patients develop often aggressively growing tumours in early teenage years and often show invasion at the time of diagnosis as well as poor response to somatostatin analogues than sporadic tumours 1,2 .
Aims
The aim of this study was to perform comparative gene expression analysis of AIP mutation-positive (AIPpos) pituitary adenomas to discover the genes/pathways responsible for the aggressive clinical phenotype of these tumours.
Methods
Gene expression analysis on normal pituitary, AIP mutation positive, familial AIPneg as well as sporadic somatotrophinomas (n=25) using the Affymetrix human Gene Chip HG-U133 Plus 2.0 array. Ingenuity Pathway Analysis (IPA) tool was used for pathway analysis. Differential expression of selected genes was validated by RT-qPCR and immunohistochemistry. In vitro stimulation of epithelial-to-mesenchymal transition (EMT) was performed on stable AIP-knockdown cells using forskolin and assessed the EMT markers by Western blotting. In vitro invasion assay was performed on AIP siRNAknocked down BxPC3 cells using BioCoat-Matrigel invasion chambers.
Ingenuity Pathway Analysis
Validation by RT-qPCR
Validation by IHC (cont.)
Validation at protein level for four downregulated (E-cadherin, Beta-catenin, ESRP1 and PERP) and one upregulated (ZEB1) genes (P ranging <0.05 to < 0.0001). Densitometric analysis of E-cadherin and ZEB1 expression. P values indicated < 0.05 (*) and < 0.01 (**); one-way ANOVA for multiple comparisons.
